TBI has been used widely in the setting of BMT over the past 3 decades. Early research demonstrated feasibility and efficacy in the myeloablative setting, in preparation first for allogenic BMT and later for autologous stem cell rescue. As experience with TBI increased, its dual roles of myeloablation and immunosuppression came to be recognized. Toxicity associated with myeloablative TBI remains significant, and this treatment is generally reserved for younger patients with excellent performance status. Reduced intensity conditioning regimens may be useful to provide immunosuppression for patients who are not candidates for myeloablative treatment. Efforts to reduce toxicity through protection of normal tissue using methods of normal tissue blocking and use of TLI, rather than TBI, continue. In the future, modalities such as helical tomotherapy, proton radiotherapy and radioimmunotherapy, may have roles in delivery of radiation to the BM and lymphoid structures with reduced normal tissue toxicity. With further investigation, these efforts may expand the therapeutic ratio associated with TBI, allowing safer delivery to a broader range of patients.
Introduction and historical perspective
Interest in the use of radiation as part of BMT arose in the mid-twentieth century. With the use of radioactive substances came the recognition that death from exposure to low-dose TBI was commonly due to marrow failure. Animal studies subsequently demonstrated the potential role of hematological infusions as rescue therapy after BM damage or eradication. [1] [2] [3] [4] [5] The first examples of humans surviving supralethal TBI in the setting of leukemia with the use of BM infusion and grafting were published in 1965. 6 During the same year, other groups described survivors of accidental irradiation who received matched marrow infusions. 7 Clinical and animal research continued over the next decade, in parallel with the development of clinical measures to support patients with decreased marrow function: these included antibiotic and antifungal agents, parenteral nutrition and blood transfusion technology that prolonged survival during the acute pretransplant and post transplant phases of treatment. In the 1970s, several groups demonstrated strong clinical results in leukemic patients receiving allogeneic BMT following chemoradiation [8] [9] [10] [11] (Table 1) . At this time, BMT were limited to patients with a sibling or related donor found to be histocompatible based on human leukocyte antigen (HLA) typing.
As survival rates after hematological malignancies increased with use of BMT, attention turned to methods of reducing toxicity and expanding potential therapeutic value. Single, large-fraction treatment was associated with death due to toxicity, most notably pneumonitis. 12 Several groups reported on methods of reduction of risk of lung toxicity, including fractionated treatment and use of lungblocking devices. Unrelated donor transplants were undertaken for patients without matched, related donors. Finally, largely to address problems identifying donors, as well as higher side-effect profiles for patients receiving unrelated donor marrow, research in the 1980s led to development of autologous SCT techniques. These allowed patients to receive their own stem cells with no concern for immunocompatibility [13] [14] [15] [16] (Table 1) . Understanding of the extremely important role of BMT in treatment of potentially fatal conditions culminated in receipt of the 1990 Nobel Prize in Physiology and Medicine by Dr E Donnell Thomas for his work on 'Organ and Cell Transplantation in the Treatment of Human Disease.' The use of TBI as a part of conditioning regimens for this type of treatment continues in the modern era, and appears to provide benefit over conditioning with chemotherapy alone in many settings [17] [18] [19] [20] (Table 1) . Although huge amounts of progress have been made with regard to optimal BMT methods in the past 50 years, myriad questions regarding technique and outcome remain.
Goals of TBI
TBI may be given as a part of BMT with therapeutic goals that are single or multifold. The first uses of TBI were with the intent of eradicating diseased marrow and/or reducing tumor burden. 8, 21, 22 This is still a common goal of TBI in both the allogeneic and autologous settings. After the myeloablative role of TBI had been established, several groups recognized the potential of TBI as an immunosuppressive. 23 This approach may allow an immunotherapeutic effect of a donor graft (graft vs tumor) to take place, targeting diseased marrow in the setting of malignant disease. Although TBI itself is not serving a myeloablative role in this setting, it is used as a means of dampening the 
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Pediatric ALL Demonstrated improved survival for children with ALL treated with TBI/Cy vs Bu/Cy for HLA-identical allogenic BMT. Kro¨ger et al. 19 
50
CML Demonstrated similar antitumor efficacy of Bu/Cy and TBI/Cy regimens for unrelated BMT, but showed higher incidence of liver and bladder toxicity with Bu/Cy. Shi-Xia et al 20 
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Leukemia Meta-analysis demonstrating improved DFS with TBI/Cy over Bu/Cy in ALL and AML.
Lower TRM was seen in all groups with TBI/Cy compared with Bu/Cy.
Benefit of TBI in the autologous BMT setting Ravindranath et al.
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Pediatric AML Demonstrated lower relapse rate after autologous BMT with TBI compared with intensive consolidation chemotherapy in childhood AML. TRM was increased in BMT group. Vaidya et al. 14 
31
Pediatric ALL Long-term follow-up of childhood ALL patients in second remission treated with autologous BMT with TBI, in absence of matched sibling donor. Demonstrated improved survival compared with historic controls after relapsed ALL. Dusenberry et al. 15 
35
AML Demonstrated improved outcomes with TBI/Cy over Bu/Cy for patients with relapsed AML undergoing autologous BMT.
Toxicity reduction: fractionation and dose-rate Altschuler et al.
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108 ALL Demonstration of low risk of pneumonitis with fractionated TBI (11 Gy in 5 fractions) Kim et al. 24 
22
ALL/AML/CML Demonstrated increased death from pneumonitis with higher dose rate TBI. Shank et al. 28 
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ALL/ANLL Demonstrated reduced incidence of pneumonitis (18 vs 50%) with 13.2 Gy in 11 fractions compared with 10 Gy in a single fraction. Thomas et al. 29 
53
ANLL Demonstrated survival advantage after 12 Gy in 6 fractions compared with 10 Gy in 1 fraction
Reduced-intensity conditioning regimens Giralt et al. 35 
15
AML/MDS Demonstrated feasibility of RIC regimens in patients ineligible for myelablative regimens. McSweeney et al. 36 
45
450 years, various malignancies Demonstrated usefulness of graft vs tumor effect in patients not eligible for myeloablative therapy; utilized mycophenolate mofetil for GVHD prophylaxis Sorror et al. 37 
144
Various malignancies Retrospective analysis demonstrating decreased incidence of grade III-IV toxicities in patients undergoing RIC vs myeloablative therapy. Higher pretransplant comorbidity scores were correlated with increased toxicity and mortality. Mielcarek et al. 38 
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Various malignancies Retrospective analysis demonstrating decreased acute GVHD after RIC vs myeloablative regimens, but described association of RIC with 'late-onset GVHD.' Baron et al. 39 
322
Various malignancies Showed potential improved graft vs tumor outcomes in patients with chronic GVHD after RIC, which was not apparent in association with acute GVHD. Kahl et al. 40 
834
Various malignancies Described improved outcomes after RIC for patients with low-grade disease (CLL, MM, NHL) compared with those with advanced myeloid/lymphoid disease. Baron et al. 41 
21
CML Demonstrated concern for increased risk of graft rejection in CML. 
Myeloablative regimens
Data regarding optimal prescribed dose and optimal dose per fraction prescribed as part of TBI are relatively limited. Earlymyeloablative TBI regimens used single, large fractions of 8-10 Gray (Gy). 8, 21, 22 As described earlier, these regimens were associated with high risk of death from interstitial pneumonitis. 12, 24 Both fractionation and reduction in dose rate were subsequently shown to potentially reduce this risk [24] [25] [26] [27] [28] (Table 1) . Data in both rodents and humans appear to indicate that dose rates o10-12 cGy/min are associated with reduced rates of pneumonitis, nausea and vomiting. 25, 29, 30 Other groups have shown that delivery of TBI in daily or twice-daily fractions appears to improve the therapeutic ratio, allowing higher radiation doses to be delivered safely. 21, 29, 31, 32 These data support use of both reduced dose-rate and fractionated TBI; however, these benefits may be offset by decreased convenience-low-dose rate treatment regimens may require up to 30 min per fraction to deliver, and twice-daily fractions may be inconvenient for both patients and treatment centers. These logistic issues may discourage some practitioners from using TBI as part of BMT regimens, and further work with regard to convenient delivery of TBI in the modern era of expansive supportive care (for example, modern anti-emetics) to further understanding of maximum tolerated dose and dose-rate is warranted.
In the latter half of the 20th century, based largely on data supporting use of fractionation and reduced dose-rate, myeloablative regimens delivering 12 Gy, twice daily, over 3 days, in combination with chemotherapy were most commonly employed. These regimens were designed to provide both immunosuppressive and cytotoxic effects as part of allogeneic BMT, and are still frequently used with these goals. Efforts to further reduce disease relapse rate through dose escalation to 15-16 Gy have not improved OS-although higher doses have been shown to decrease relapse rates, this benefit appears to be offset by increased mortality unrelated to relapse. 31, 33, 34 Thus, more, cannot simply be presumed to be better. Interestingly, the noted increase in death from toxicity appears to be restricted to the 6-12 month period post transplant. 32 Various other regimens, including modest dose escalation to 13-14 Gy, and single daily treatments, have been studied without clear impact on patient outcomes.
Reduced-intensity conditioning regimens
In their various forms, myeloablative regimens are associated with significant risk and toxicity, and access is often limited to patients who are o50 years of age with excellent performance status. In the 1990s, feasibility of reducedintensity conditioning (RIC) regimens consisting of lowerdose TBI and/or fludarabine was published by several groups. 35, 36 These regimens appeared to allow donor engraftment with reduced risk of acute, life-threatening toxicity; the cytotoxic effect from such regimens is minimal, and they are delivered in order to provide immune suppression and allow donor marrow engraftment-tumor cell death is largely dependent on a graft vs tumor effect.
McSweeney et al. 36 demonstrated the feasibility of use of a regimen employing 2 Gy delivered as a single dose, with or without fludarabine, with cyclosporine and mycophenolate mofetil as GVHD prophylaxis in older patients. Other groups have demonstrated acceptable rates of donor engraftment and decreased toxicity with 2 Gy, single-dose, low-dose rate (7 cGy/min) TBI in the setting of both related and unrelated donor transplantation. [37] [38] [39] Overall relapsefree survival rates were examined by Kahl et al., 40 who noted that subsets of patients, including those with diagnoses of CLL, multiple myeloma and non-Hodgkin's lymphoma appeared to fare better than others after this type of regimen. Other groups have found that risk of graft rejection may be higher for patients with myelodysplastic syndrome and CML. 41 Marks et al. 42 compared cohorts of patients receiving myeloablative therapy vs RIC for adult ALL, and found no difference in mortality on multivariate analysis-although relapse rates were increased with RIC regimens, age-adjusted survival was the same. Various other reduced-intensity fractionation regimens have been investigated at centers worldwide. Generally speaking, relapse rates appear to be higher when non-myeloablative regimens are employed; however, increased disease-related mortality may be offset by decreased death from toxicity. As RIC regimens rely more heavily on graft vs tumor response, providing immune suppression so that donor marrow may engraft and relying on the graft marrow for tumor cell destruction, effectiveness varies across disease type, as would be expected. With the currently available treatment options, myeloablative regimens appear to provide benefit to patients who can tolerate such aggressive treatment, when relapse-free survival benefit outweighs risk of death from toxicity, and are still commonly employed. Clearly, however, no perfect TBI prescription currently exists, and many questions regarding dose requirements and optimal dose rate and fractionation exist.
Morbidity associated with current regimens for TBI
Clearly, toxicity associated with TBI remains one of the most important factors in determining treatment regimens for individual patients. During radiation of the entire body, toxicity to essentially every organ system must be considered; however, understanding toxicity associated uniquely with radiotherapy is complicated by the many other treatments that are simultaneously received by patients undergoing BMT-these may include antibiotic, antifungal and antiviral agents, immunosuppressive drugs, pain medications, chemotherapeutics and myriad others. As described previously, interstitial pneumonitis was observed to occur in B50% of patients receiving TBI via a single, large fraction of 8-10 Gy, with 50% of cases proving fatal. 12 Even when fractionated and low-dose-rate TBI is employed with concurrent chemotherapy, the rate of interstitial pneumonitis may approach 25%. 43 Clearly, fractionation and dose-rate reduction lower the risk of development of this life-threatening toxicity; however, analysis is complicated by further observation that CMV is associated with many cases of interstitial pneumonitis, and transplant patients are at high risk for contraction or reactivation of CMV. 43 The multifactorial nature of interstitial pneumonitis developing during or after BMT serves as an example that can be likened to many toxicities occurring in this setting-because they result from so many different factors, they are particularly difficult to fully understand and prevent.
Acute toxicities associated with TBI The most common acute toxicities following TBI, listed in Table 2 , include nausea and vomiting, although these are largely preventable with modern anti-emetic drugs. Parotitis may occur after the first 1-2 fractions, and generally subsides within 1-2 days. 44 Dry mouth and mucositis may occur 5-10 days after TBI. Parotitis appears to be a side effect uniquely associated with TBI; however, other acute side effects are generally due to combinations of agents and illness experienced by patients in the acute BMT setting. End-organ damage and late effects after TBI Many of the toxicities associated with TBI may result in end-organ damage. These can include cataract formation in 30-40% (80-90% of those receiving a single fraction of 8-10 Gy), 20, 45 gonadal failure, 46 thyroid dysfunction, kidney dysfunction 47, 48 and decreased bone mineral density. 49 Survivors are at known risk for chronic oral and dental complications after TBI, with xerostomia being reported by patients as having a major impact on quality of life 1 year after BMT. 50 In a recent analysis of late effects and quality of life of childhood cancer survivors, TBI was strongly associated with short stature and endocrine dysfunction. 51 Survivors of childhood ALL treated with TBI have also been demonstrated to be at increased risk for cardiometabolic traits, including central adiposity, hypertension, insulin resistance and full-blown metabolic syndrome compared with survivors treated with conventional chemotherapy. 52 Venoocclusive disease of the liver may occur in 10-70% of patients, 53 although risk appears to be modulated by use of concurrent drugs, 20 57 demonstrated a 3.3% incidence of development of a solid tumor 20 years after BMT. This risk was increased for the 67% of patients who received irradiation compared with those who did not; however, interestingly, this excess risk was observed only in patients who received radiation at 30 years of age or younger. 57 In another large analysis of 19 299 BMT patients, Curtis et al. 58 observed the risk of solid tumor to be 2.2% 10 years after BMT, and 6.7% 15 years after. Again, an inverse relationship was observed between the frequency of second cancer and age at time of transplantation. Radiotherapy was observed to increase the risk of second cancers, with this risk being significantly higher for patients receiving at least 10 Gy to the total body compared with those receiving o10 Gy. 58 This is potentially of interest in light of the risks and benefits observed with RIC regimens that may employ single fractions of 2 Gy. Socie´et al. 59 have published similar findings in a cohort of 3182 children undergoing allogeneic BMT for acute leukemia. The incidence of secondary solid cancers was found to be 11% at 15 years, with increased risk among patients who received high-dose TBI, and those o5 years of age at the time of transplantation. 59 In addition to solid tumors, patients are also at risk for further hematological malignancies-one of the most dreaded of these is therapyrelated myeloid neoplasm, including myelodysplasia and AML. Krishnan et al. 60 analyzed 612 patients having undergone high-dose chemoradiotherapy with autologous stem cell rescue for Hodgkin's disease and non-Hodgkin's lymphoma; on multivariate analysis, the contribution of TBI to risk of therapy-related myeloid neoplasm was not statistically significant; however, this risk was notably increased for patients who underwent priming with VP-16 for peripheral stem cell collection. 60 As demonstrated time and time again, risk of severe endorgan toxicity and development of SMN are multifactorial in this patient population. Fractionation and reduced doserate TBI appear to decrease risk of interstitial pneumonitis and cataract formation, and most acute toxicities appear to be related to overall TBI dose and dose-rate. Some population-based data demonstrate a direct relationship between TBI dose and development of SMN. Further large studies and long-term comparison studies may help to further elucidate the optimal balance between aggressive treatment of the primary malignancy, and reducing risk of life-threatening toxicity and SMN.
Protection of normal tissue during TBI
As the delicate balance between the need for aggressive treatment and limiting toxicity associated with this treatment becomes increasingly clear in the setting of TBI, the need for consideration of methods of toxicity-reduction beyond dose and dose-rate is emphasized. One method for potentially reducing the risk profile associated with TBI is reduction of the volume of exposed normal tissue. Current methods for delivery of TBI require the target volume to encompass the entire body, using either an anteriorposterior/posterior-anterior (AP-PA) or opposed lateral approach. For individuals other than babies and small children, this generally requires an extended source to surface distance so that the entire body may be encompassed in the beam. This type of treatment requires each and every organ to be considered an 'organ at risk' during delivery of radiotherapy; in keeping with the nomenclature, 'total body irradiation' is delivered, when radiation of only the BM, lymphoid regions and central nervous system (CNS) might be adequate from a therapeutic standpoint.
Use of physical blocks to reduce normal tissue exposure Current methods for reducing the volume of total tissue exposed include placement of blocks to reduce dose to critical normal structures. With recognition of the potentially fatal nature of interstitial pneumonitis associated with TBI has come use of lung blocks, designed to include the pulmonary volumes identified on AP-PA films, and reduction of dose delivered to the mid-plane of the lungs. Animal studies have demonstrated that lung blocks may protect resident cell populations within the lungs, while still permitting full marrow engraftment, 61 and reduction of lung dose has been demonstrated to improve OS after TBI in patients with compromised pulmonary function before BMT. 62 Along the same lines, eye shields may be employed to reduce risk of cataract formation, 63 and kidney shields are occasionally used. 28, 64, 65 Although physical blocks are useful in specific settings such as those described above, many vital organs cannot feasibly be blocked during delivery of TBI as this blocking would also block areas of marrow and lymph nodes requiring treatment.
TLI for immunosuppression during BMT
Recent work has demonstrated that limiting radiation dose to lymphoid tissue may serve an immunosuppressive role and protection from GVHD, with reduced toxicity when compared with TBI. TLI has been shown in animal studies to cause changes in the constitution of the T-cell population; explicitly, TLI may result in increased proportions of natural killer T cells as compared with conventional T cells. 66, 67 Natural killer T cells, in turn, may prevent GVHD by inhibiting actions of conventional T cells that mediate GVHD. 66, 68 Clinical studies in humans using TLI-based regimens have been very promising. Lowsky et al. 69 described 37 patients with lymphoid malignancies or acute leukemia who were treated with 800 cGy total TLI, over 10 fractions. All patients were of age and/or co-morbidity status that rendered them unsuitable for myeloablative BMT. Radiation was delivered using fields to encompass major lymph node regions, as well as the thymus and spleen, and patients received concurrent antithymocyte globulin. Those authors report very low incidence of acute GVHD (3% grade II or higher), which they note to be considerably lower than that described in most studies of RIC regimens. The TLI regimen appeared to allow engraftment, and did not appear to adversely affect the antitumor properties of the graft. TLI regimens may have the appeal of offering improved protection from GVHD when compared with RIC regimens, while also limiting the volumes of normal tissue exposed when compared with any TBI regimen. Certainly, further study is warranted; increased odds of early CMV viremia have been demonstrated following TLI, 70 and other potential toxicities have yet to be explored. Having said this, TLI represents an appealing alternative to TBI in certain populations. Efforts to further improve TLI regimens are underway, with use of combinations of chemotherapy and TLI to optimize tumor control and reduce TRM 71 described in the literature.
Future directions: increased conformality and potential for dose escalation Potential use of helical tomotherapy As techniques for delivery of radiotherapy continue to progress, options for delivering more conformal treatment to either the 'total body' (BM, nodal regions and CNS) or only the lymphoid regions, may potentially become available. Helical tomotherapy is one potentially attractive technology that employs a megavoltage linear accelerator mounted on a computed tomography gantry. This type of device allows the beam source to continually rotate around the patient. Simultaneously, the couch, or patient placement device, moves perpendicularly to the beam source. This allows the beam to move in a spiral or helical pattern relative to the patient. The beam can be modulated with a multileaf collimator. During treatment planning, these qualities allow large volumes to be delineated and treated, while neighboring volumes may be spared. Zhuang et al. 72 recently performed a dosimetric comparison of TBI delivered via helical tomotherapy compared with the more traditional, extended SSD approach. The target volume for treatment was the entire body less the right and left lungs. After treatment planning with both techniques, the average dose delivered to the target volume was improved with tomotherapy, and median right and left lung doses were reduced with this technique. 72 Treatment planning time did not appear to differ significantly between the two techniques, although treatment delivery took a longer period of time when tomotherapy was employed. Wong et al. 73 performed a similar study evaluating use of tomotherapy to treat the total marrow (target region skeletal bone) as well as the major lymph node chains, spleen and sanctuary sites. They demonstrated a 1.7-7.5-fold reduction in median organ dose with these techniques compared with conventional TBI. Additionally, dose-volume histogram analysis predicted that dose escalation up to 20 Gy could potentially be feasible and safe with this technique. Total marrow irradiation using helical tomography was delivered to one patient, who experienced a blood count nadir followed by successful engraftment, accompanied by limited nausea and vomiting, and no erythema, oral mucositis or esophagitis. 73 Certainly, these preliminary studies support further investigation into clinical feasibility of use of helical tomotherapy for delivery of TBI with sparing of critical normal structures. This technique may allow delivery of myeloablative doses to a broader range of patients if toxicity to normal critical structures can be limited clinically (Table 3) .
Potential use of proton beam radiotherapy
Proton beam radiotherapy is a second potential technology, which may eventually allow total marrow and/or lymphoid irradiation to be delivered with minimal toxicity (Table 3 ). The heavy, charged nature of protons causes them to stop within tissue and deposit the majority of their energy at their stopping point-this produces the observed 'Bragg-peak.' The Bragg-peak may be placed within a delineated target volume, allowing dose to be deposited within the target with minimal exit dose. This stands in stark contrast to photon-based treatment, when exit dose is unavoidable. Proton radiotherapy is employed for delivery of craniospinal radiation in pediatric malignancies at several centers; this type of treatment allows radiation to be delivered to the brain and spinal cord with minimal exit dose through the heart, lungs and gastrointestinal and genitourinary organs. 74, 75 Potential exists for the target volume to be expanded to include all of the skeletal bones as well as lymphoid groups and organs. To our knowledge, the dosimetric feasibility of this type of treatment has not been explored.
Potential use of radioimmunotherapy
Perhaps the ultimate conformal approach to delivery of radiotherapy involves use of radionucleotides conjugated to antibodies that recognize cell-surface Ags. Such agents, recognizing and binding to CD20, are currently available for patients with B-cell non-Hodgkin's lymphoma, and have been employed as part of RIC regimens for allogeneic BMT in the phase II setting. 76 An agent targeted to BM would be penultimate in allowing directed delivery of radiation. Extensive work to extend the success of radioimmunotherapy to other forms of cancer is currently underway with goals of expanding cell surface targeting, and tailoring radionucleotides employed to specific clinical situations 77 (Table 3) .
Use of increasingly conformal radiotherapy for delivery of treatment to the BM and related sites has potential to widen the therapeutic ratio currently associated with radiation in the setting of BMT: employment of 'total marrow irradiation' or 'total marrow and lymphoid irradiation' rather than 'total body irradiation' may allow myeloablative dose delivery with reduced or minimal normal tissue effects, and stands to potentially benefit many subsets of patients-both those who cannot tolerate myeloablative therapy with current techniques, and those who may benefit from dose escalation that is currently unacceptably toxic (Figure 1 ). Certainly, it seems that further research and clinical trials examining the role of tomotherapy, proton therapy and/or radioimmunotherapy for delivery of this type of treatment are warranted (Table 3) .
Conclusions and areas for future investigation
Over the past 60 years, the role of BMT has expanded from a desperate rescue effort to a treatment modality that is used broadly. Work in the late 20th century demonstrated the multiple ways in which TBI as part of BMT may be employed-as a myeloablative therapy, an immunosuppressive component, or both. Unfortunately, the therapeutic ratio associated with BMT remains very narrowalthough higher radiation doses appear to offer improved survival from the primary malignancy, doses are limited by normal tissue toxicity. Comparisons between treatment regimens remain difficult because of lack of randomized comparisons within the literature, and because most investigations are done retrospectively by single institutions. Still, radiation dose and dose-rate appear to correlate directly with both relapse-free survival and overall toxicity, including risk of SMN. As we approach research goals regarding TBI in the 21st century, modalities to improve conformality may offer new opportunities with regard to this therapy. Reducing normal tissue exposed may allow escalation of myeloablative TBI doses, and may allow patients who cannot currently tolerate myeloablative radiation to do so. Randomized, cooperative, clinical investigations with regard to these opportunities are certainly warranted and necessary.
